This surge presents both a challenge and a profound opportunity: how can fitness and wellness professionals confidently and safely support clients navigating rapid, medication-driven transformation
Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
Popular GLP-1 weight-loss drugs, such as Ozempic and Wegovy, are typically intended for long-term use, but research suggests that 50% to 75% of people stop taking these medications within a year
59,60 GLP-1RAs reduce epicardial fat, which is known to play a key role in triggering atrial remodelling in obesity
We all get tired after a long day, a demanding week, or a late night
Tirzepatide vs Ozempic Results: Which One is Better